Watson Announces Global Generics Management Team

PARSIPPANY, N.J., Oct. 31, 2012 /CNW/ - Watson Pharmaceuticals, Inc. (NYSE: 
WPI) today announced the Global Generics management team, following the 
announcement of the completion of the acquisition of the Actavis Group for EUR 
4.25 billion.  The combination creates the world's third largest generic 
pharmaceutical company, with anticipated pro forma combined 2012 revenues in 
excess of $8 billion. 
"Since the announcement of our intention to acquire Actavis in April 2012, we 
have been working to ensure that we have the management structure in place to 
capitalize on the commercial momentum of this combined organization," said 
Paul Bisaro, President and CEO of Watson.  "Led by Siggi Olafsson, President, 
Global Generics, we begin operations as one company, with a commercial team 
that recognizes the extraordinary commercial expertise of senior leaders from 
both companies.  We are structured to ensure that we immediately create value 
for customers and shareholders." 
Managing Expanded Global Generic Footprint The combined company has operations 
in more than 60 countries, with a top 10 position in over 33 markets including 
the U.S., U.K., Canada, Australia, Nordics and Russia.  The Company is also 
the fastest growing generic pharmaceutical company in Western Europe.  The 
combined company will be geographically diverse, with approximately 40 percent 
of its generics revenues coming from outside of the U.S. 
As integration planning progressed, Watson management defined the global 
structure of its generics business, including its U.S. and international 
businesses and R&D team. 
Global Generics Commercial Management Team Watson's U.S. generic business, 
with approximately 10 percent U.S. market share, will be led by Andrew Boyer.  
Mr. Boyer joined Watson in 1998 as Associate Director of Marketing in Generics 
and has taken on roles with increasing responsibility, serving most recently 
as Senior Vice President, Sales and Marketing.  Before joining Watson, Mr. 
Boyer held management positions with Lederle/American Cyanamid and Barr 
Watson's Canada and Latin America business will be led by Jean-Guy Goulet.  
Mr. Goulet joined Watson in 2011 as President, Canada and Mexico for Watson's 
Canadian subsidiary Cobalt Pharmaceuticals.  Prior to joining Watson, Mr. 
Goulet was President and CEO of ratiopharm Canada. Mr. Goulet began his career 
in the quality control department at Technilab, which was later acquired by 
ratiopharm.  He rapidly moved up within the organization, gaining increasing 
responsibilities in operations, sales, marketing and business development.  In 
2002, he was appointed President of the Commercial division of ratiopharm 
Canada, based in Toronto, before his appointment as the company's President 
and CEO in 2006. 
Watson's European generics business, led by Lars Ramneborn, has been 
structured into seven country clusters of approximately equal revenue size and 
with similar market structures and dynamics.  Mr. Ramneborn was Vice President 
of Strategy at Actavis, a position he held since March 2010.  Mr. Ramneborn 
has more than 20 years experience in the pharmaceutical industry and joined 
Actavis from Zentiva, where he was Vice President and a member of the board of 
directors since 2003.  Prior to joining Zentiva he was Vice President 
CEE/Middle East for five years for Galena/IVAX, which later merged into Teva. 
Watson's Asia and Middle East and Africa (MEA) generics business, led by 
Hordur Thorhallsson, has been structured into five country clusters, based on 
geographic location as well as similarities in market structure and commercial 
dynamics.  Mr. Thorhallsson was Executive Vice President of MEA and Asia 
Pacific sales for Actavis.  He joined the company in 2000 and worked as Vice 
President of Operations from 2002 to 2003.  From 2003 to 2006, Mr. 
Thorhallsson served as Managing Director at Actavis hf. in Iceland, before 
transferring to the company's corporate level as Managing Director of Business 
Watson's Australian business will be led by Karen McTavish.  Ms. McTavish 
joined Watson in 2012 to lead the company's Australian business following the 
acquisition of Ascent Pharmaceuticals.  Ms. McTavish joined Watson from Apotex 
Pty Ltd, in Sydney, Australia, where she served as National Sales and 
Marketing Director since 2006.  Under Ms. McTavish's leadership, Apotex Pty 
Ltd reported sales growth averaging approximately 33 percent each year.  Prior 
to her Australian assignment, she held several positions in Apotex in Canada 
from 1992 to 2006.  Prior to Apotex, she held positions of increasing 
responsibility with NCR Canada Ltd. 
Watson's Global Generics R&D function will be led by Hafrun Fridriksdottir, 
Ph.D.  Dr. Fridriksdottir served most recently as Actavis' Vice President of 
R&D, U.S., Europe and ROW, residing in the U.S. and serving on the company's 
U.S. executive management board.  From 2002 to 2008 she was Vice President of 
R&D, EU and ROW at Actavis.  Dr. Fridriksdottir joined the generic 
pharmaceutical development company Omega Farma in 1997 as Divisional Manager, 
Development, and was promoted to Managing Director in early 2002, a post she 
held until the company was acquired by Actavis in late 2002.  Dr. 
Fridriksdottir holds a Ph.D. in Physical Pharmacy from the University of 
Watson's Specialty Pharmaceutical Development function will be led by Stefan 
Sveinsson.  Mr. Sveinsson will lead a separate function that will focus on 
critical technologies for driving future product initiatives in both the 
Global Generics and Global Brands business. Mr. Sveinsson joined Actavis in 
1993, serving most recently as Executive Vice President of R&D.  Mr. Sveinsson 
has a Master's degree in Pharmaceutics from Dalhousie University in Canada. 
Wolter F. Kuizinga will lead Watson's International Business Development 
function and Daniel N. Motto will lead Watson's U.S. Business Development 
Third Party Business Watson's third-party sales business, which includes both 
Actavis' Medis business and Watson's Specifar Pharmaceuticals, will ultimately 
operate under the Medis name and will be led by Valur Ragnarsson.  Mr. 
Ragnarsson joined Actavis' Medis division in 2001.  He was appointed Managing 
Director in 2003 and Executive Vice President in 2008.  Mr. Ragnarsson has an 
MSc in Pharmacy from the University of Iceland and has more than 20 years of 
experience in the pharmaceutical industry. 
Additional resources are available at 
About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc. (NYSE: WPI) is 
a global, integrated specialty pharmaceutical company focused on developing, 
manufacturing and distributing generic, brand and biosimilar products.  The 
Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and 
international headquarters in Zug, Switzerland. 
Watson is the world's third-largest generics manufacturer, with more than 750 
products marketed globally through operations in more than 60 countries.  
Watson's global branded pharmaceutical business develops and markets products 
principally in Urology and Women's Health, and is committed to developing and 
marketing biosimilars products in Women's Health, Oncology and other 
therapeutic categories.  In addition, Watson is the fourth-largest U.S. 
generic pharmaceutical product distributor through its Anda, Inc. business, 
and also develops and out-licenses generic pharmaceutical products outside of 
the U.S. through its Medis third-party business.  Watson has announced that it 
will adopt a new global name – Actavis  – effective in 2013. 
Forward-Looking Statement 
Statements contained in this press release that refer to Watson's estimated or 
anticipated future results or other non-historical facts are forward-looking 
statements that reflect Watson's current perspective of existing trends and 
information as of the date of this release. For instance, any statements in 
this press release concerning prospects related to Watson's strategic 
initiatives, product introductions and anticipated financial performance are 
forward-looking statements. It is important to note that Watson's goals and 
expectations are not predictions of actual performance. Watson's performance, 
at times, will differ from its goals and expectations. Actual results may 
differ materially from Watson's current expectations depending upon a number 
of factors affecting Watson's business. These factors include, among others, 
the inherent uncertainty associated with financial projections; successful 
integration of the Actavis acquisition and the ability to recognize the 
anticipated synergies and benefits of the Actavis acquisition; the difficulty 
of predicting the timing and outcome of pending or future litigation and 
government investigations and risks that an adverse outcome in such litigation 
or investigations could render Watson liable for substantial damages or 
penalties; risks that resolution of patent infringement litigation through 
settlement could result in investigations or actions by private parties or 
government authorities or agencies; the impact of competitive products and 
pricing; risks related to fluctuations in foreign currency exchange rates; 
periodic dependence on a small number of products for a material source of net 
revenue or income; variability of trade buying patterns; changes in generally 
accepted accounting principles; risks that the carrying values of assets may 
be negatively impacted by future events and circumstances; the timing and 
success of product launches; the difficulty of predicting the timing or 
outcome of product development efforts and regulatory agency approvals or 
actions, if any; risks and uncertainties normally incident to the 
pharmaceutical industry, including product liability claims and the 
availability of product liability insurance on reasonable terms; market 
acceptance of and continued demand for Watson's products; difficulties or 
delays in manufacturing; the availability and pricing of third party sourced 
products and materials; successful compliance with governmental regulations 
applicable to Watson's facilities, products and/or businesses; changes in the 
laws and regulations, including Medicare, Medicaid, and similar laws in 
foreign countries affecting, among other things, pricing and reimbursement of 
pharmaceutical products and the settlement of patent litigation; and such 
other risks and uncertainties detailed in Watson's periodic public filings 
with the Securities and Exchange Commission, including but not limited to 
Watson's Annual Report on Form 10-K for the year ended December 31, 2011 and 
Watson's Quarterly Report on Form 10-Q for the period June 30, 2012. Except as 
expressly required by law, Watson disclaims any intent or obligation to update 
these forward-looking statements. 
CONTACTS:       Investors:  Lisa DeFrancesco                                    
  Office: (862) 261-7152 Mobile: (862) 222-5076 
Media:  Charlie Mayr Office: (862) 261-8030 Mobile: (862) 222-3528 
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ) 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Watson Pharmaceuticals, Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Watson Pharmaceuticals, Inc.
ST: New Jersey
-0- Oct/31/2012 23:40 GMT
Press spacebar to pause and continue. Press esc to stop.